Day One Biopharmaceuticals
CA - BrisbanePharmaceutical
Focus: Day One Biopharmaceuticals is a focused oncology company with a marketed RAF kinase inhibitor (OJEMDA/tovorafenib) and an active pipeline targeting pediatric and adult brain tumors and melanoma. The company operates as a specialty pharma player with a lean, community-focused structure.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Open Jobs
8
Should You Work at Day One Biopharmaceuticals?
AI assessmentDay One is a mission-driven oncology specialist best suited for candidates seeking focused science and pediatric impact, but carries private company risks around funding, scale, and long-term stability.
Why Work Here
- Lead role in pediatric oncology with OJEMDA approved for low-grade glioma, an underserved indication with high unmet need
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Help build intelligence for Day One Biopharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.